uniQure CEO Matthew Kapusta Sells Shares Valued at $7.29 Million
CEO Matthew Kapusta executed a planned sale of 164,429 shares in uniQure, valued at over $7.29 million.
Key Points
- Matthew Kapusta, CEO of uniQure, sold 164,429 shares valued at approximately $7.29 million on June 17, 2026.
- Shares of NasdaqGS:QURE traded near $46.37 on Monday, with a market cap of about $2.92 billion and a 52-week range from $8.73 to $71.50.
- Analysts from Barclays and Goldman Sachs have recently updated their ratings and price targets for uniQure.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
On June 17, 2026, Matthew Kapusta, the CEO and Managing Director of uniQure N.V. (NasdaqGS:QURE), executed a planned sale of 164,429 shares. The transaction was valued at approximately $7.29 million, with shares sold at an average price of $44.32.
Insider Buying and Selling at uniQure N.V.
Matthew Kapusta's recent transactions include both buying and selling activities. On June 18, 2026, he sold 41,671 shares at $50 each under a planned sale and also purchased 4,656 shares at $31.71. Additionally, he sold 62,581 shares at no cost on the same day. Another insider, Madhavan Balachandran, was involved in both buying and selling on June 17, 2026, selling 11,685 shares at $45.06 and buying the same amount at $24.97.
Other Institutional Activity in uniQure
Several institutional investors have adjusted their positions in uniQure. AVORO Capital Advisors LLC reduced its holdings by 190,405 shares, ending with 5,959,595 shares valued at approximately $97.44 million, marking a 3.1% decrease. In contrast, Aberdeen Group PLC increased its stake by 1,627,746 shares, now holding 5,306,386 shares worth about $86.76 million, a 44.2% increase. JPMorgan Chase & Co also decreased its position by 97,160 shares to 2,837,466 shares valued at $41.80 million, a 3.3% reduction.
uniQure N.V. Stock Down 6.1%
Shares of uniQure traded near $46.37 on Monday. The company has a market cap of approximately $2.92 billion and a forward P/E ratio of -15.58, indicating it isn't profitable. With a beta of 1.001, the stock has a 52-week low of $8.73 and a high of $71.50. Its 50-day moving average is $24.13, and the 200-day moving average is $27.53. The company maintains a strong current ratio of 10.40 and a quick ratio of 9.97, though it carries a high debt-to-equity ratio of 365.37.
$QURE stock price
Daily closing prices, year to date. Not investment advice.
Analysts Set New Price Targets
On June 18, 2026, Barclays upgraded uniQure to a 'buy' with a price target of $65. Goldman Sachs maintained a 'hold' rating with a target of $46, while Leerink Partners kept their 'buy' rating with a $70 target. RBC Capital also maintained a 'buy' rating with a $65 target. The consensus recommendation remains a 'strong buy', with an average target price of $58.75 among 11 analysts.
About uniQure
uniQure N.V., based in Amsterdam, Netherlands, is a biotechnology company focused on developing gene therapies for rare and serious diseases. Its key products include HEMGENIX for hemophilia B and AMT-130 for Huntington's disease. The company is also working on treatments for epilepsy, ALS, and Fabry disease. Founded in 1998, uniQure has a strong presence in the healthcare sector and employs 221 people.
Bottom Line
Matthew Kapusta's recent stock sale is part of planned transactions and doesn't necessarily indicate a lack of confidence in uniQure. Investors keep an eye on such insider activities as they can provide insights into executive actions. It's important to remember that these insider trades are disclosed after they occur. Analysts' recent ratings updates offer varied perspectives on the stock's potential, reflecting both optimism and caution.
Get uniQure N.V. alerts
New 13F filings, insider trades, and analyst moves on $QURE, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.